American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 1072-1080, December 2009

Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients

  • Dominic S.C. Raj, MD

      Affiliations

    • Division of Renal Diseases and Hypertension, George Washington University, Washington, DC
  • ,
  • Juan J. Carrero, PhD

      Affiliations

    • Department of Renal Medicine, Karolinska Institutet, Stockholm, Sweden
  • ,
  • Vallabh O. Shah, PhD

      Affiliations

    • Department of Biochemistry, University of New Mexico Health Sciences Center, Albuquerque, NM
  • ,
  • Abdul R. Qureshi, MD

      Affiliations

    • Department of Baxter Novum, Karolinska Institutet, Stockholm, Sweden
  • ,
  • Peter Bárány, MD

      Affiliations

    • Department of Renal Medicine, Karolinska Institutet, Stockholm, Sweden
  • ,
  • Olof Heimbürger, MD

      Affiliations

    • Department of Renal Medicine, Karolinska Institutet, Stockholm, Sweden
  • ,
  • Bengt Lindholm, MD

      Affiliations

    • Department of Baxter Novum, Karolinska Institutet, Stockholm, Sweden
  • ,
  • Jennet Ferguson, BA

      Affiliations

    • Division of Renal Diseases and Hypertension, George Washington University, Washington, DC
  • ,
  • Pope L. Moseley, MD

      Affiliations

    • Department of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM
  • ,
  • Peter Stenvinkel, MD

      Affiliations

    • Department of Renal Medicine, Karolinska Institutet, Stockholm, Sweden
    • Corresponding Author InformationAddress correspondence to Peter Stenvinkel, MD, Department of Renal Medicine K56, Karolinska University Hospital at Huddinge, Karolinska Institutet, 141 86 Sweden

Received 8 January 2009; accepted 23 June 2009. published online 07 September 2009.

Background

CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD14 levels in hemodialysis patients. We hypothesized that sCD14 level increase may link to cytokine activation and protein-energy wasting, predisposing to increased mortality risk.

Study Design

Prospective observational study of prevalent hemodialysis patients.

Setting & Participants

211 prevalent hemodialysis patients, median age of 65 years, with 29 months of vintage dialysis time followed up for mortality for a median of 31 months.

Predictors

Tertiles of baseline circulating sCD14 levels corresponding to less than 2.84, 2.85 to 3.62, and greater than 3.63 μg/mL.

Outcome

The major outcome of interest was all-cause mortality.

Measurements

sCD14 and endotoxin, together with other markers of inflammation and protein-energy wasting.

Results

Median sCD14 level was 3.2 μg/mL (25th to 75th percentile, 2.7 to 3.9). sCD14 level correlated positively with C-reactive protein, interleukin 6, endotoxin, and pentraxin 3 levels and negatively with serum albumin level, muscle mass, and handgrip strength. Patients with increased sCD14 levels had lower body mass index and increased prevalence of muscle atrophy. Patients within the highest sCD14 tertile had a crude morality hazard ratio of 1.94 (95% confidence interval, 1.13 to 3.32) that persisted after adjustment for multiple confounders (hazard ratio, 3.11; 95% confidence interval, 1.49 to 6.46). In patients with persistent inflammation, the presence of a concurrent sCD14 level increase gradually increased mortality risk, but this effect was less than multiplicative and failed to show a statistical interaction.

Limitations

Those inherent to an observational study.

Conclusions

sCD14 level is associated with inflammation and protein-energy wasting in hemodialysis patients. It is a strong and independent predictor of mortality that warrants further assessment in the clinical setting regarding its usefulness as a complementary prognosticator to other general inflammatory markers.

Index Words: Endotoxin, interleukin 6 (IL-6), protein-energy wasting, C-reactive protein (CRP), hemodialysis, pentraxin 3

 

 Originally published online as doi:10.1053/j.ajkd.2009.06.022 on September 7, 2009.

 D.S.C.R. and J.J.C. contributed equally to this work.

PII: S0272-6386(09)00940-8

doi:10.1053/j.ajkd.2009.06.022

Refers to article:

  • Soluble CD14 and Endotoxin Levels in Hemodialysis Patients: A Tale of 2 Molecules

    Victor F. Seabra, George Thomas, Bertrand L. Jaber
    American Journal of Kidney Diseases December 2009 (Vol. 54, Issue 6, Pages 990-992)

American Journal of Kidney Diseases
Volume 54, Issue 6 , Pages 1072-1080, December 2009